Lodestone Biomedical

Hanover, United States Founded: 2015 • Age: 11 yrs
Provider of magnetic nanoparticle platform technology for in vivo biomarker monitoring in immuno-oncology

About Lodestone Biomedical

Lodestone Biomedical is a Healthcare company based in Hanover (United States) founded in 2015 by Lidia Valdes. Provider of magnetic nanoparticle platform technology for in vivo biomarker monitoring in immuno-oncology. Lodestone Biomedical has raised $1.19 million across 5 funding rounds from investors including MassChallenge. Its chief executive, as recorded, is Lidia Valdes. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Assays and Drug Discovery. Its competitors include BioAmp Diagnostics, Araceli Biosciences and Hematogenix; 1 of its 3 listed competitors has raised funding.

Company details

Lodestone Biomedical was founded in 2015 in Hanover, United States, as a provider of magnetic nanoparticle platform technology focused on immuno-oncology. The Immunotherapy Response Indication System (IRIS) is utilized to interrogate binding states of functionalized magnetic nanoparticles in needle-implantable biosensor probes. Real-time signals of treatment efficacy and response are monitored within the tumor-immune microenvironment. Operations center on in vivo biomarker detection for clinical applications.

  • Headquarters Hanover, United States
  • Founders Lidia Valdes
  • Sectors
    Healthcare
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website lodestonebiomedical.com
  • Social LinkedIn
Key Metrics
  • Annual Revenue
    $957.21 K (USD)
    103
    as on Dec 31, 2023
  • Net Profit
    -$59.27 K (USD)
    67
    as on Dec 31, 2023
  • Total Equity Funding
    $1.19M (USD)

    in 5 rounds

  • Latest Funding Round
    $75K (USD), Seed

    Jun 2025

  • Investors

Funding Insights of Lodestone Biomedical

Lodestone Biomedical has successfully raised a total of $1.19M across 5 strategic funding rounds. The most recent funding activity was a Seed round of $75 thousand completed in June 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $1.19M
  • Total Rounds 5
  • Last Round Seed β€” $75,000
  • Investors Count 1

All 5 funding rounds of Lodestone Biomedical with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jun 2025$75,000Seed––
–
Dec 2021$450,000Seed––
–
Apr 2020$110,000Seed––
–
Jul 2017$550,000Seed––
–
Jun 2015Grant––
Valuation history

1 investors in total: 1 institutional.

Investors in Lodestone Biomedical

Lodestone Biomedical has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include MassChallenge.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
Early-stage entrepreneurs are accelerated through MassChallenge's program.
masschallenge.orgBoston, United States
Premium access

Investor details for Lodestone Biomedical

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Lodestone Biomedical

1 people are tracked at Lodestone Biomedical (1 in leadership).

NameRoleGroup
Lidia Valdes
Co-Founder & CEOLeadership
Premium access

Complete people profiles for Lodestone Biomedical

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Lodestone Biomedical

3 dated milestones of Lodestone Biomedical across 10 years, from founding to its latest funding, stage changes and deals.

  1. Founded Lodestone Biomedical is founded.
  2. Funding First funding round.
  3. Funding Latest funding round, Seed, of $75K.

Competitors of Lodestone Biomedical

Lodestone Biomedical has 3 listed competitors in our database, 1 of them funded. They include BioAmp Diagnostics, Araceli Biosciences and Hematogenix.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
bioampdx.com2017Berkeley, United States
Developers of diagnostic tests that help to treat patient with a specific antibiotic
aracelibio.com2020United States$15.95M
Scientific tools for tissue and cell-based biomarker discovery are developed.
hematogenix.com2007Tinley Park, United States
It serves as a service provider in pharma.
Premium access

Detailed competitors of Lodestone Biomedical

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Life Sciences Platforms & Tools

3 companies that operate in the same segment as Lodestone Biomedical (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Medidata is recognized as a leading provider of SaaS solutions for clinical research.
1999New York, New York, United StatesUSD 41.5 M
AI-based solutions for health management are provided.
2015Dallas, Texas, United StatesUSD 2.8 B1,111
Real-world health data is provided for research and decisions.
2012Menlo Park, California, United StatesUSD 259.16 M
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about Lodestone Biomedical

Lodestone Biomedical was founded in 2015.

Lodestone Biomedical is headquartered in Hanover, United States. It is registered at Hanover, New Hampshire, United States.

Lidia Valdes is the CEO of Lodestone Biomedical, as recorded in our data. They have also founded this company.

Lodestone Biomedical is a funded company, having raised a total of $1.19M across 5 funding rounds to date.

Annual revenue of Lodestone Biomedical is $957.21K as on Dec 31, 2023.

Lodestone Biomedical was founded in 2015 in Hanover, United States, as a provider of magnetic nanoparticle platform technology focused on immuno-oncology. The Immunotherapy Response Indication System (IRIS) is utilized to interrogate binding states of functionalized magnetic nanoparticles in needle-implantable biosensor probes. Real-time signals of treatment efficacy and response are monitored within the tumor-immune microenvironment. Operations center on in vivo biomarker detection for clinical applications.

Lodestone Biomedical's top competitors include Araceli Biosciences, BioAmp Diagnostics and Hematogenix.

Lodestone Biomedical has 1 investor. Key investors include MassChallenge.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available